Targovax announces completed enrollment in the ONCOS-102 trial in anti-PD1 refractory melanoma
· The trial is now fully recruited, with a total of 21 patients enrolled Oslo, Norway, 3 March 2020 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces that it has completed patient enrollment in the phase I trial with ONCOS-102 in combination with Keytruda (pembrolizumab) in patients with advanced anti-PD1 checkpoint inhibitor (CPI) refractory melanoma. In this trial, ONCOS-102 immune activation is being tested in patients with advanced, unresectable melanoma who have had disease